Skip to main content

Published locations for Idelalisib shows long-term safety, efficacy for relapsed CLL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Idelalisib shows long-term safety, efficacy for relapsed CLL

User login

  • Reset your password
  • /content/idelalisib-shows-long-term-safety-efficacy-relapsed-cll
  • /fedprac/article/199657/cll/idelalisib-shows-long-term-safety-efficacy-relapsed-cll
  • /hematologynews/article/199657/cll/idelalisib-shows-long-term-safety-efficacy-relapsed-cll
  • /oncologypractice/article/199657/cll/idelalisib-shows-long-term-safety-efficacy-relapsed-cll
  • /fedprac/avaho/article/199657/cll/idelalisib-shows-long-term-safety-efficacy-relapsed-cll
  • /hematology-oncology/article/199657/cll/idelalisib-shows-long-term-safety-efficacy-relapsed-cll
  • /hematologytimes/article/199657/cll/idelalisib-shows-long-term-safety-efficacy-relapsed-cll
  • /b-cell-lymphoma-icymi/article/199657/cll/idelalisib-shows-long-term-safety-efficacy-relapsed-cll